LianBio (LIAN) Stock Price, News & Analysis

Company Overview

LianBio is a biopharmaceutical company focused on developing and commercializing innovative medicines for patients in China and other major Asian markets. The company works with global pharmaceutical and biotechnology partners to advance therapies that address significant unmet medical needs, with an emphasis on efficient regional development and commercialization.

Rather than relying solely on internally discovered compounds, LianBio has pursued licensing and collaboration agreements to obtain rights to selected drug candidates and technologies. Its activities have included clinical development, regulatory preparation, and commercialization planning for therapies in areas such as cardiovascular disease, oncology, and other serious conditions.

LianBio was established to help bridge global biopharmaceutical innovation with healthcare markets in Asia. The company has operated across the United States and Asian markets through partnerships and regional development activities. Its leadership has included Carsten Brunn, Ph.D., who served as president and chief executive officer and has experience in international biotechnology and pharmaceutical operations.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: $0.03 to $0.06
• 52-Week Range: $0.27 to $4.99
• Volume: 23 shs
• Average Volume: 1.04 million shs
• Market Capitalization: $5.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 3/27/2023
• Today: 10/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LIAN
• CIK: 1831283
• Web: www.lianbio.com
• Phone: 609-486-2308
• Fax: N/A
• Employees: 110
• Year Founded: 2019

Profitability

• EPS (Trailing Twelve Months): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 0.02
• P/E Growth: N/A
• Net Income: -$110.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.17%
• Return on Assets: -30.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.06
• Quick Ratio: 10.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.71 per share
• Price / Book: 0.02

Miscellaneous

• Outstanding Shares: 108,063,000
• Free Float: 99,861,000
• Market Cap: $5.51 million
• Optionable: Not Optionable
• Beta: 0.23